I-Bristol-Myers Squibb, I-CHECKMATE-76K, FDA, melanoma, I-Opdivo
I-Nivolumab igunyazwe yi-FDA yokwelashwa kwe-adjuvant ye-Stage IIB/C melanoma
Nov 2023: Nivolumab (Opdivo, Bristol-Myers Squibb Company) was granted approval by the Food and Drug Administration as an adjuvant therapy for Stage IIB/C melanoma in patients 12 years of age and older who had undergone complete..
I-BMS, I-Bristol Myers squibb, immunotherapy, I-melanoma ye-metastatic, nivolumab futhi relatlimab, nivolumab futhi relatlimab-rmbw, I-Opdualag, USFDA
Inhlanganisela yokuqala ye-LAG-3-Blocking antibody, i-Opdualag™ (i-nivolumab ne-relatlimab-rmbw), igunyazwe yi-FDA ezigulini ezinemelanoma engahlanjululwayo noma ye-metastatic.
Ephreli 2022: I-US Food and Drug Administration (i-FDA) igunyaze i-Opdualag (nivolumab ne-relatlimab-rmbw), inhlanganisela yomthamo ongaguquki wezinga lokuqala le-nivolumab kanye ne-relatlimab elawulwa njengokufakwa emthanjeni okukodwa, i-f.
Ukulinganisa kwenkampani Immunocore Limited, Kimmtrak, I-metastatic uveal melanoma, tebentafusp-tebn, i-melanoma yemvelo
I-Tebentafusp-tebn igunyazelwe i-melanoma ye-uveal engabukeki noma ye-metastatic
Mashi 2022: I-Tebentafusp-tebn (Kimmtrak, Immunocore Limited), i-bispecific gp100 peptide-HLA-directed CD3 T cell engager, inikezwe ilayisense I-Food and Drug Administration ye-HLA-A*02:01-positive-positive-positive cells with unresectab. .
I-CD-38, FDA, Umkhathizwe, i-ejenti ye-immunomodulatory, i-melphalan flufenamide, i-myeloma eminingi, I-NCT02963493, I-Oncopeptides AB, Pepaxto
IMelphalan flufenamide ithola imvume ku-FDA nge-myeloma ephindelela noma ephikisayo
Agasti 2021: I-Melphalan flufenamide (i-Pepaxto, i-Oncopeptides AB) ihlanganiswe ne-dexamethasone inikezwe ukugunyazwa okusheshayo yi-Food and Drug Administration ezigulini ezikhulile ezine-myel eminingi ebuyele emuva noma ephikisayo.
KEYTRUDA, Merck, I-NCT02362594, I-Pembrolizumab, KHUMBULA, USFDA
I-Pembrolizumab yamukelwa yi-FDA ekwelashweni nge-adjuvant kwe-melanoma
NgoFebhuwari 15, 2019, i-pembrolizumab (KEYTRUDA, Merck) yagunyazwa yiFood and Drug Administration yokwelapha i-adjuvant yeziguli ezinemelanoma ngokubandakanyeka kwe(ama)lymph node ngemuva kokuhlinzwa ngokuphelele. Imvume ..
Ukuhlinzwa kweBariatric, Delhi, India, USA
Ukuhlinzwa kwe-Bariatric kunganciphisa ubungozi be-melanoma
Ngaphezu kokulahlekelwa isisindo okusheshayo nokuhlala njalo nezinye izinzuzo zezempilo, ukuhlinzwa nge-bariatric manje kuhlotshaniswa nengozi encishisiwe engama-61% ye-melanoma ebulalayo, okuwumdlavuza wesikhumba obulala kakhulu ohlotshaniswa kakhulu ne-s ..